Lamivudineinteractions
lamivudine 150 MG / zidovudine 300 MG Oral Tablet
This is the interactions section of this product’s FDA label — what the manufacturer documented for this drug. It is not a check of your medication list, and a drug missing from it has not been cleared: licensed clinical databases list far more interactions than any single label does. Before combining medicines, ask a pharmacist, who can check everything you take at once and will do it for free.
Named on this label
Every name above is printed in the text below. This is not the full set of drugs that interact with this one — it is the set this manufacturer wrote down.
Drug interactions
Agents antagonistic with zidovudine: Concomitant use should be avoided.
Hematologic/bone marrow suppressive/cytotoxic agents: May increase the hematologic toxicity of zidovudine.
Sorbitol: Coadministration of lamivudine and sorbitol may decrease lamivudine concentrations; when possible, avoid chronic coadministration.
Agents antagonistic with zidovudine: Concomitant use should be avoided.
Hematologic/bone marrow suppressive/cytotoxic agents: May increase the hematologic toxicity of zidovudine.
Sorbitol: Coadministration of lamivudine and sorbitol may decrease lamivudine concentrations; when possible, avoid chronic coadministration.
7.1 Zidovudine
Agents Antagonistic with Zidovudine Concomitant use of zidovudine with the following drugs should be avoided since an antagonistic relationship has been demonstrated in vitro:
Stavudine
Doxorubicine
Nucleoside analogues, e.g., ribavirin Hematologic/Bone Marrow Suppressive/Cytotoxic Agents Coadministration with the following drugs may increase the hematologic toxicity of zidovudine:
Ganciclovir
Interferon alfa
Ribavirin
Other bone marrow suppressive or cytotoxic agents
7.2 Lamivudine
Sorbitol Coadministration of single doses of lamivudine and sorbitol resulted in a sorbitol dose-dependent reduction in lamivudine exposures. When possible, avoid use of sorbitol-containing medicines with lamivudine-containing medicines.
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective March 29, 2023. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
This page reproduces regulatory text for reference. It is not medical advice, and KenyRx is not a pharmacy or a prescriber. Talk to a doctor or pharmacist about whether a medicine is right for you.
See what it costs — price without insurance